NCT07463768
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07463768
Title Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. (MIVONU)
Acronym MIVONU
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors French Innovative Leukemia Organisation
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Angers Angers 49933 France Details
CH côte Basque Bayonne 64109 France Details
CHU Besançon Besançon 25030 France Details
Hopital d'Instruction des Armées Percy Clamart 92140 France Details
CHU Henri Mondor Créteil 94000 France Details
CHU Grenoble Grenoble 38043 France Details
Chru de Lille - Hopital Claude Huriez Lille 59037 France Details
CHU de Limoges Limoges 87000 France Details
CHU de Nantes Nantes 44093 France Details
CHU de Nîmes - Institut de Cancérologie du Gard Nîmes 30029 France Details
Hôpital Saint Louis Paris 75010 France Details
CH de Perpignan Perpignan 66046 France Details
Hôpital Haut-Lévêque Pessac 33604 France Details
Hôpital Lyon-Sud Pierre-Bénite 69310 France Details
Chu de Rennes - Hopital Pontchaillou Rennes 35033 France Details
Centre Henri Becquerel Rouen 76038 France Details
CHU de TOULOUSE - IUCT ONCOPOLE Toulouse 31059 France Details
Chru Bretonneau Tours 37044 France Details
CHRU Nancy Vandœuvre-lès-Nancy 54500 France Details
Gustave Roussy Villejuif 94800 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field